

FOLFOX6, which achieved a 15% RR and 4.2-month PFS.<sup>13</sup> Although our study could not evaluate enough data for PFS and MST due to the short observation period after the approval of oxaliplatin in Japan, both the FOLFOX regimens we used seem to be beneficial as first-line and second-line therapy for refractory or advanced CRC in a Japanese population, with an overall response rate which is comparable to Western figures regarding first-line and second-line therapy. FOLFOX6 is the most useful of the FOLFOX regimens because it is simple and can be administered on an outpatient basis. When we use oxaliplatin in FOLFOX regimens, because 85 mg/m<sup>2</sup> is the approved dose for usage in Japan, the treatment is adapted for this dose, even in the mFOLFOX6 regimen.

In conclusion, the FOLFOX regimens we used were found to demonstrate good efficacy as chemotherapy regimens in our population, with an acceptable overall toxicity profile. However, attention must be paid to the occurrence of peripheral sensory neuropathy, which may influence a patient's quality of life, while also limiting the continuation of such treatment.

## References

1. Poon MA, O'Connell MJ, Moertel CG, et al. (1989) Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. *J Clin Oncol* 7:1407-1418
2. Levi F, Zidani R, Misset JL (1997) Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer: International Organization for Cancer Chronotherapy. *Lancet* 350:681-686
3. Giacchetti S, Perpoint B, Zidani R, et al. (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. *J Clin Oncol* 18:136-147
4. Douillard JY, Cunningham D, Roth AD, et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. *Lancet* 355:1041-1047
5. Machover D, Diaz-Rubio E, de Gramont A, et al. (1996) Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. *Ann Oncol* 7:95-98
6. Levi F, Perpoint B, Garufi C, et al. (1993) Oxaliplatin activity against metastatic colorectal cancer: a phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. *Eur J Cancer* 29A:1280-1284
7. Diaz-Rubio E, Sastre J, Zaniboni A, et al. (1998) Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. *Ann Oncol* 9:105-108
8. Becouarn Y, Ychou M, Ducreux M, et al. (1998) A phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. *J Clin Oncol* 8:2739-2744
9. de Gramont A, Vignoud J, Tournigand C, et al. (1997) Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. *Eur J Cancer* 33:214-219
10. Raymond E, Buquet-Fagot C, Djelloul S, et al. (1997) Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast, and ovarian cancers. *Anticancer Drugs* 8:876-885
11. Goldberg RM, Sargent DJ, Alberts SR, et al. (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol* 22:23-30
12. de Gramont A, Figer A, Bonetti A, et al. (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. *J Clin Oncol* 18:2938-2947
13. Tournigand C, Andre T, de Gramont A, et al. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. *J Clin Oncol* 22:229-237
14. Braun MS, Adab F, Seymour MT, et al. (2003) Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer. *Br J Cancer* 89:1155-1158

## Phase I Study of Combination Therapy with S-1 and Weekly Docetaxel for Advanced Gastric Cancer

TOMOHIRO OZAKI<sup>1</sup>, KENJI TAMURA<sup>1</sup>, TAROH SATOH<sup>2</sup>, TAKAYASU KURATA<sup>3</sup>, TOSHIO SHIMIZU<sup>1</sup>, MASAKI MIYAZAKI<sup>2</sup>, ISAMU OKAMOTO<sup>2</sup>, KAZUHIKO NAKAGAWA<sup>2</sup> and MASAHIRO FUKUOKA<sup>2</sup>

<sup>1</sup>Department of Medical Oncology, Kinki University School of Medicine, Nara Hospital, Otoda, Ikoma, Nara;

<sup>2</sup>Department of Medical Oncology, Kinki University School of Medicine, Ohno-higashi, Osaka-sayama, Osaka;

<sup>3</sup>Cancer Chemotherapy Center, Osaka Medical College, Daigaku, Takatsuki, Osaka, Japan

**Abstract.** *Background:* The primary objective of this study was to determine the maximum tolerated dose (MTD), the toxicity profile and the recommended dose (RD) for phase II of a combination of S-1 and weekly administration of docetaxel. *Patients and Methods:* Patients with histologically diagnosed recurrent or unresectable locally advanced gastric cancer were enrolled. A fixed oral dose of 80 mg/m<sup>2</sup> S-1 was given for 3 weeks. Docetaxel was infused intravenously on day 1, 8 and 15, repeated every 5 weeks. A pharmacokinetic study was also performed. *Results:* A total of 14 patients were enrolled. One dose-limiting toxicity (DLT) (grade 3 diarrhea with febrile neutropenia) occurred at level 2. DLTs occurred in 3/5 patients at level 3, (grade 3 stomatitis, with febrile neutropenia or continuous grade 4 neutropenia). The pharmacokinetic study suggested no drug interactions. Overall response and disease control rates were 20% and 80%, respectively. The response rate at the RD (level 2) was 50%. Overall survival was 9.4 months. *Conclusion:* RD was level 2 (80 mg/m<sup>2</sup> of S-1 for 3 weeks and 20 mg/m<sup>2</sup> of docetaxel on day 1, 8 and 15, every 5 weeks). Dose intensities of S-1 and docetaxel were 48 mg/m<sup>2</sup>/week and 12 mg/m<sup>2</sup>/week, respectively. This regimen showed promising activity for advanced gastric cancer.

The incidence and mortality of gastric cancer has been declining, however, it remains one of the most common causes of cancer-related death (1). It is often diagnosed in advanced stage or recurrent disease, both of which are incurable, and carries a dismal prognosis with a short

median survival. The one year survival rate is approximately 50% in stage III gastric cancer patients, and 25% in stage IV. Although gastric cancer has been regarded as a resistant tumor, several clinical trials have revealed that some chemotherapeutic agents are effective. 5-Fluorouracil (5-FU)-containing regimens are considered as standard chemotherapy because they provide survival benefit and improvement in quality of life compared with best supportive care (2-4). Hence in the 1980's, many combinations of drugs, 5-FU/doxorubicin/mitomycin (FAM) (5), 5-FU/doxorubicin/methotrexate (FAMTX) (6), etoposide/doxorubicin/cisplatin (EAP) (7), epirubicin/cisplatin/5-FU (ECF) (8), 5-FU/doxorubicin/cisplatin (FAP) (9) and 5-FU/cisplatin (FP) (10, 11) were reported in the treatment of gastric cancer. Although response rates were improved by 40-70%, the survival advantage over single agent 5-FU alone was not significant and severe adverse effects were observed (12). To improve efficacy of chemotherapy against gastric cancer, development of novel agents and combinations which have higher antitumor activity with favorable safety profiles is crucial.

S-1, a fourth-generation oral fluoropyrimidine, is a formulation of tegafur (FT), 5-chloro-2,4-dihydropyridine (CDHP) and potassium oxonate (Oxo) at a molar ratio of 1:0.4:1 (13). FT is the prodrug for cytotoxic fluorouracil (FU) and CDHP prevents its degradation. CDHP is a potent and competitive inhibitor of dihydropyrimidine dehydrogenase, which reduces the degradation of FU and allows efficacious concentrations to enter the anabolic pathway. The diarrheagenic property of FU is a result of its phosphorylation in the intestine, primarily by orotate phosphoribosyltransferase (OPRT). Oxo is a competitive inhibitor for OPRT. Thus, the protective effect of Oxo is due to its ability to reduce phosphorylation of FU. Thus, one component of S-1, CDHP, reduces the degradation of cytotoxic FU, and another component, Oxo, potentially reduces its GI toxicity. Phase II studies of S-1 monotherapy in patients with advanced gastric cancer showed an overall

*Correspondence to:* Kenji Tamura, MD, Ph.D., Chemotherapy Treatment Center for Outpatients National Cancer Center Hosp Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan. Tel: +81 3 35422511, Fax: +81 3 35423815, e-mail: ketamura@ncc.go.jp

*Key Words:* Gastric cancer, phase I study, S-1, docetaxel, weekly chemotherapy.

response rate of 26-49% with the most relevant side-effects being fatigue, diarrhea and neutropenia (14-16). Recently, phase II studies of S-1 plus cisplatin (17), or S-1 plus irinotecan (18) have been evaluated and showed promising response rates.

Docetaxel is a semisynthetic taxoid which enhances microtubule assembly and inhibits the depolymerization of tubulin (19); it has broad antitumor activity against malignancies. It demonstrated promising single-agent efficacy in gastric cancer (20-23) and was therefore investigated in different combination regimens. The combinations of docetaxel with 5-FU (24), capecitabine (25, 26), irinotecan (27) and cisplatin (28) have demonstrated high efficacy. The triplet combination of docetaxel/cisplatin and 5-FU has significantly prolonged overall survival compared to cisplatin plus 5-FU (29). Thus, docetaxel is one of the key drugs playing an integral part in routine combination regimens against gastric cancer.

Based on the clinical activity of both docetaxel and S-1, and the fact that there is no cross resistance or synergistic anti-tumor effect between docetaxel and 5-FU (30) or S-1 (31, 32) *in vitro* or *in vivo*, two Japanese investigators combined docetaxel and S-1 in a clinical trial (33-35). The recommended dose of docetaxel was 40 mg/m<sup>2</sup> on day 1, in combination with S-1 80 mg/m<sup>2</sup> on days 1-14, every 3-4 weeks. The total dose of docetaxel was restricted by neutropenia, with around 70% of patients having grade 3 or 4 neutropenia (33). The real dose intensities of S-1 and docetaxel were around 40 mg/m<sup>2</sup>/week and 10 mg/m<sup>2</sup>/week, respectively. A weekly administration schedule of docetaxel has been reported as a safe and effective treatment for advanced gastric cancer (26, 36, 37). The aims of the present study were to determine the maximum-tolerated dose (MTD) of docetaxel with weekly administration in combination with S-1 in order to achieve higher dose intensities of both drugs with a feasible toxicity profile and to establish the recommended dose (RD) for Phase II trials.

**Patients and Methods**

*Eligibility criteria.* Patients, aged 20 to 75 years, with at least one measurable lesion of pathologically proven inoperable or recurrent gastric cancer were enrolled. Inoperability was determined on the basis of clinical evaluation, radiological imaging, laparoscopy or laparotomy with failed resection. Patients who had no more than two previous treatment regimens not including taxanes (docetaxel or paclitaxel) or S-1 were eligible.

Other eligibility criteria were: Eastern Cooperative Oncology Group performance status 0 or 1; estimated life expectancy of at least 3 months; adequate renal function (serum creatinine <1.5x upper limit of the reference range (ULN)), adequate hepatic function (serum bilirubin <1.5x ULN; transaminases <2.5x ULN) and adequate hematological function (hemoglobin >8 g/dl, leukocytes >4,000/ $\mu$ L and thrombocytes >100,000/ $\mu$ L). No other anti-tumor therapy was allowed 28 days prior to treatment.

Table I. Patient characteristics.

Characteristics	Number of patients
Number of patients (evaluable)	14
Age, years; median (range)	61 (31-76)
Gender	
Male	11
Female	3
Performance status (ECOG)	
0	2
1	12
Histology	
Not assessable 2	
Well-differentiated	0
Moderately differentiated	3
Poorly differentiated	9
Extent of disease	
Primary site only	2
Primary and metastatic sites	9
Metastasis only	3
Previous treatment	
None	7
Surgery alone	2
Surgery and adjuvant chemotherapy	2
Surgery and intra-peritoneal chemotherapy	1
Systemic chemotherapy alone	1
Intra-peritoneal chemotherapy alone	1

Eligibility also included the ability to reliably tolerate and comply with oral medication. Patient compliance was recorded using chemotherapy diary cards. Pre-treatment evaluation included a complete medical history and physical examination, basic laboratory evaluation and staging of the underlying malignancy with either ultrasound, chest radiograph or computed tomography (CT) scan.

Main exclusion criteria were follows: pregnancy or breast feeding, symptomatic infectious disease, pulmonary fibrosis or interstitial pneumonia, grade 3 or severe hemorrhage/bleeding, grade 2 or severe peripheral neuropathy, symptomatic peripheral effusion or ascites, past history or allergic reaction to polysorbate 80, obstructive bowel disease or severe diarrhea, congestive heart failure, uncontrolled angina pectoris, or arrhythmia, uncontrolled diabetes or hypertension, symptomatic brain metastasis and active concomitant malignancy.

Patient characteristics are given in Table I. This was a phase I study, conducted at the Department of Medical Oncology, Kinki University, Japan. This study was approved by the institutional review board of Kinki University and all patients provided written informed consent.

*Drug administration.* Patients received a dose of intravenous docetaxel administered as a 60 min infusion on day 1, 8 and 15, and oral S-1 administered at a fixed dose of 80 mg/m<sup>2</sup>/day on days 1-21, every 5 weeks (Figure 1). Patients were treated for at least two cycles unless disease progression or unacceptable toxicity was observed. The initial starting dose of docetaxel was 15 mg/m<sup>2</sup> (level 1) (Table II). Dose




Figure 1. Treatment schedule of combination therapy with S-1 and docetaxel. Administration of S-1 80 mg/m<sup>2</sup>/day orally from day 1-21. Administration of docetaxel was given by drip infusion within 60 min. on day 1, 8 and 15. At all dose levels, the administration cycle was repeated every 5 weeks.

escalation was conducted in increments of 5 mg/m<sup>2</sup> up to 25 mg/m<sup>2</sup> (level 3). No intra-individual dose escalation was performed. Docetaxel was only administered on day 8 and 15 if WBC and platelets were >2,000/ $\mu$ l and >75,000/ $\mu$ l, respectively, with non-hematological toxicity <grade 3 and allergic reaction/AST/ALT/pneumonitis <grade 2. In case of grade 3 neutropenia or thrombocytopenia, or grade 2 diarrhea or mucositis, S-1 administration was interrupted until recovery. Patients were not allowed to escalate or reduce the dose of S-1. If any DLTs were observed, docetaxel was reduced once by one dose level for subsequent courses.

**DLTs and MTD.** Toxicities were evaluated according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2 (38). DLTs were defined as follows: (a) grade 4 neutropenia lasting 5 days or longer; (b) febrile neutropenia (grade 3 or 4 neutropenia with fever ( $\geq 38.5^{\circ}\text{C}$ )); (c) grade 4 thrombocytopenia; (d) grade 3 or 4 non-hematological toxicity except for nausea, vomiting, anorexia and general fatigue; (e) failure to administer docetaxel on day 8; (f) failure to administer docetaxel on day 15, even if postponed for one week; and (g) failure to administer S-1 for 14 days continuously during treatment.

Assessment of DLTs was conducted only in the first treatment cycle. Three patients per dose level were planned to be included. In case of one DLT, three further patients were treated at that level. MTD was defined as at least two out of three or three out of six patients with DLT at a given dose level. Throughout this study, the prophylactic administration of granulocyte colony-stimulating factor (G-CSF) was not allowed.

**Evaluation during therapy.** Hematological and biochemical tests, performance status and clinical assessment of symptoms were monitored at least every week. Tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) (39). All partial or complete responses were confirmed for a minimum of 4 weeks. Patients were considered evaluable for response if they received at least one complete cycle of therapy, unless treatment was stopped due to early toxicity. Time to progression and overall survival were estimated using the Kaplan-Meier method.

**Pharmacokinetics.** The pharmacokinetics of docetaxel and S-1 were studied during the first cycle of therapy. For docetaxel, 5 ml blood samples were taken from each patient at the following time-points: prior to treatment, 30 min into the drug infusion, at the end of docetaxel infusion, and 30 min, 1 h, 2 h, 3 h, 4 h, 7 h and 24 h after the end of the infusion. For S-1, 5 ml blood samples were taken from each patient at the following time-points: prior to dose, and

Table II. Dose escalation scheme and DLTs in course 1.

Level	1	2	3
Dose of docetaxel (mg/m <sup>2</sup> )	15	20	25
Dose of S-1 (mg/m <sup>2</sup> )	80	80	80
Number of patients	3	6	5
Median number of courses (range)	2 (2-9)	2 (2-5)	1 (1-2)
Number of patients with any DLT/Number of patients	0/3	1/6	3/5
ANC: <500/mm <sup>3</sup> for >5 days	0	0	2
Febrile neutropenia	0	1 <sup>a</sup>	2
Other grade 3-4 non-hematological toxicity	0	1 <sup>a</sup>	3 <sup>b</sup>
Inability to receive docetaxel on day 8 or day 15	0	0	1 <sup>c</sup>
Inability to receive S-1 more than 14 days	0	0	0

ANC: absolute neutrophil count; <sup>a</sup>Same patient with grade 3 diarrhea with febrile neutropenia; <sup>b</sup>All patients with grade 3 stomatitis; <sup>c</sup>Due to neutropenia.

1 h, 2 h, 4 h, 8 h and 24 h after dose. Initial administration of S-1 was started at 8 h after the end of docetaxel infusion on day 1. To evaluate drug-drug interactions between docetaxel and S-1, the pharmacokinetic analysis of docetaxel was conducted on day 1 and day 8, and that of S-1 was conducted on day 7 and day 8. On day 1 only, S-1 was administered in the evening, after the blood correction for pharmacokinetic analysis of docetaxel at 7 h after infusion. All blood samples were centrifuged immediately and the separated plasma samples were frozen at  $-20^{\circ}\text{C}$  until analysis. The plasma samples were thawed at ambient temperature, then vortexed and centrifuged for 5 min at 3,000 rpm to remove fibrous materials. Pharmacokinetic analysis for docetaxel was performed according to Yoshida *et al.* (34). Pharmacokinetic analysis for S-1 was carried out as described elsewhere (17).

Table III. Hematological and non-hematological adverse events.

Adverse events	Level 1 (n=3)				Level 2 (n=6)				Level 3 (n=5)			
	1	2	3	4	1	2	3	4	1	2	3	4
<b>Hematological</b>												
Leukocytopenia	1	0	0	0	0	0	1	0	0	0	1	1
Neutropenia	1	0	0	0	0	0	1	0	0	0	0	2
Anemia	0	0	0	0	1	0	1	0	1	0	3	0
Thrombocytopenia	2	0	0	0	2	0	0	0	0	0	0	0
<b>Non-hematological</b>												
Nausea/vomiting	2	0	0	0	2	0	0	0	0	0	0	0
Anorexia	0	1	0	0	1	3	0	0	1	1	0	0
Fatigue	2	0	1	0	5	0	0	0	1	3	0	0
Stomatitis	2	0	0	0	0	0	0	0	0	0	3	0
Constipation	1	1	0	0	1	1	0	0	1	1	0	0
Diarrhea	1	1	0	0	0	1	1	0	2	1	0	0
AST/ALT	0	1	0	0	0	0	0	0	0	0	0	0
Skin rash	1	0	0	0	0	0	0	0	0	0	0	0
Pneumonia	0	0	0	0	0	0	0	0	0	0	0	0
Infection	1	1	0	0	0	1	0	0	0	0	0	0
Febrile neutropenia	0	0	0	0	0	0	1	0	0	0	2	0

AST: aspartate aminotransferase; ALT: alanine aminotransferase.

**Results**

*Patient characteristics.* A total of 14 patients with a median age of sixty-one years (range 31-76 years) were recruited for this study. Patient characteristics are listed in Table I. One patient was clinically diagnosed with primary ovarian cancer and following oophorectomy, a Krukenberg tumor with primary gastric cancer was diagnosed. Five patients received prior chemotherapy. Two patients had uracil-tegafur (UFT) and carboplatin/paclitaxel as adjuvant therapy, respectively. Two patients had received chemotherapy only, of systemic administration with cisplatin/5-FU and irinotecan, or of intra-peritoneal infusion with paclitaxel. Seven patients had not received any prior treatment.

*Sequence of dose levels studied and DLTs.* Three patients started on level 1 (S-1 80 mg/m<sup>2</sup>/day with docetaxel 15 mg/m<sup>2</sup>) and no DLTs were observed (Table II). The next cohort of three patients received dose level 2 (S-1 80 mg/m<sup>2</sup>/day with docetaxel 20 mg/m<sup>2</sup>) and as one patient experienced grade 3 diarrhea and febrile neutropenia (DLT), this group was expanded to six patients. None of the three additional patients experienced DLT. The next cohort of three patients received dose level 3 (S-1 80 mg/m<sup>2</sup>/day with docetaxel 25 mg/m<sup>2</sup>) and one patient experienced grade 3 stomatitis and grade 2 diarrhea (DLT), so this group was expanded to six patients. Two additional patients

experienced DLT (grade 3 stomatitis, febrile neutropenia and continuous grade 4 neutropenia). One of these patients could not be treated with docetaxel on day 8 in the 1st cycle because of neutropenia. Thus, three of five patients had DLTs at level 3. In these five patients, the most frequent DLTs were stomatitis, febrile neutropenia and continuous neutropenia. Therefore, level 2 was considered as the recommend dose for the phase II study. The median number of cycles received per patient was two (range one to nine). Dose intensities of S-1 and docetaxel were 48 mg/m<sup>2</sup>/week and 12 mg/m<sup>2</sup>/week, respectively.

*Adverse effects.* All the patients were evaluated for adverse effects which are summarized in Table III. No grade 3 adverse effects were observed at level 1 except for fatigue in one patient. One patient at level 2 had grade 3 diarrhea with febrile neutropenia as DLT, however, no other grade 3 or non-hematological adverse effect was observed at the level in the repeated cycle. No grade 4 hematological adverse effects were observed at level 1 or 2. At level 3, 3 out of 5 patients had grade 3 stomatitis and 2 of them also had febrile neutropenia; furthermore, 3 out of 5 patients had grade 3 anemia while two out of 5 patients had grade 4 neutropenia.

*Pharmacokinetics (PK) analyses.* Blood samples for PK analyses were available for 13 out of the 14 patients, including all 5 patients at the optimal dose level (20 mg/m<sup>2</sup>).

Table IV. Plasma concentrations of docetaxel.

	Level 1 (n=3)			Level 2 (n=5)			Level 3 (n=5)		
	$C_{max}$ (ng/mL)	$AUC_{0-t}$ (ng•h/mL)	$AUC_{0-A}$ (ng•h/mL)	$C_{max}$ (ng/mL)	$AUC_{0-t}$ (ng•h/mL)	$AUC_{0-A}$ (ng•h/mL)	$C_{max}$ (ng/mL)	$AUC_{0-t}$ (ng•h/mL)	$AUC_{0-A}$ (ng•h/mL)
Day 1 (-S-1)	205	238	-	521	522	616	591	835	1547
Day 8 (+S-1)	240	308	-	597	547	581	379	555	1028

$C_{max}$ : maximum observed concentration; AUC: area under the concentration-time curve.

Table V. Plasma concentrations of FT, 5-FU, CDHP and Oxo.

	FT		5-FU		CDHP		Oxo	
	$C_{max}$ (ng/mL)	$AUC_{0-A}$ (ng•h/mL)	$C_{max}$ (ng/mL)	$AUC_{0-A}$ (ng•h/mL)	$C_{max}$ (ng/mL)	$AUC_{0-A}$ (ng•h/mL)	$C_{max}$ (ng/mL)	$AUC_{0-A}$ (ng•h/mL)
Day 7 (n=8)	2526±615	15189±3184	151.3±70.6	810.5±349.3	299.8±175.8	1342.4±624.3	76.1±21.1	414.2±118.8
Day 8 (n=8)	2509±380	14882±2219	156.4±62.7	765.0±304.4	307.5±149.5	1368.8±537.2	93.8±46.4	491.0±216.3

FT: tegafur; 5-FU: fluorouracil; CDHP: 5-chloro-2,4-dihydropyridine; Oxo: potassium oxonate;  $C_{max}$ : maximum observed concentration; AUC: area under the concentration-time curve; Values are expressed as mean ± standard deviation (SD).




Figure 2. Plasma concentrations of docetaxel with and without administration of S-1 (day 1 vs. day 8).

The PK parameters for docetaxel are shown in Table IV. The plasma concentration of docetaxel with or without S-1 (day 1 vs. day 8) are shown in Figure 2. Although  $C_{max}$ ,  $AUC_{0-t}$ ,  $AUC_{0-A}$  of docetaxel on day 8 were slightly lower than those of day 1, PK parameters for docetaxel were equivalent between day 1 and day 8. The PK parameters for FT, 5-FU, CDHP and Oxo are shown in Table V. The plasma concentration of FT, 5-FU, CDHP and Oxo with administration or not of docetaxel (day 7 vs. day 8) are shown in Figure 3. PK parameters of S-1 were equivalent on day 7 and on day 8. Thus, no drug interactions between S-1 and docetaxel were observed.

**Efficacy.** Response and survival data were updated in October 2006. Ten patients were assessable for tumor response (Table VI). Four patients were considered not evaluable for response, because of early drop-out due to early toxicity. Two patients were also considered not evaluable for RECIST criteria, because there were only primary tumors and no metastatic site (Table I). One patient was considered not evaluable for response after entry because there was only peritoneal dissemination and no target lesion (Table VI). There were 2 partial responses at level 2 and no complete response. The overall response rate was 20% (2 out of 10). The response rate at the




Figure 3. Plasma concentrations of 5-fluorouracil (5-FU), tegafur (FT), potassium oxonate (Oxo), and 5-chloro-2,4-dihydropyridine (CDHP) with and without administration of docetaxel (day 7 vs. day 8).

recommended dose (level 2) was 50% (2 out of 4). The disease control rate was 80% (8 out of 10). All fourteen patients were assessable for survival (Figure 4). The median survival time was 9.4 months and the median time to progression was 2.4 months. The median survival time at the recommended dose (level 2) was 10.0 months.

**Discussion**

Current key drugs for the treatment of gastric cancer are cisplatin, taxoids (paclitaxel and docetaxel), irinotecan and 5-fluorouracil (5-FU) or its derivative drugs (such as doxifluridine, capecitabine, tegafur and UFT). 5-FU-based combinations are considered as a standard chemotherapy for first-line treatment of advanced gastric cancer because they provide survival benefit compared with best supportive care (2-4) In western countries, triplet combinations such as epirubicin/cisplatin/5-FU (ECF) or docetaxel/cisplatin/5-FU (DCF) (29) regimens are the current standard, however, they are sometimes not recommended practically because of their severe hematological toxicity. S-1 is a novel oral fluoropyrimidine derivative. Single use of S-1 has revealed promising response in advanced gastric cancer with acceptable side-effects being stomatitis, fatigue, diarrhea

Table VI. Tumor response.

Level	Number of patients	CR	PR	SD	PD	RR (%)
1	2	0	0	2	0	0
2	4	0	2	1	1	50
3	4	0	0	3	1	0
Total	10	0	2	6	2	20

CR: complete response; PR: partial response; SD: stable disease, PD: progressive disease; RR: response rate; Tumor responses were evaluated using RECIST criteria.

and neutropenia (14-16), but no hand-foot syndrome which is frequently caused by capecitabine. Based on the clinical activity of S-1 monotherapy, phase II studies of S-1 plus cisplatin (17), S-1 plus irinotecan (18) and S-1 plus docetaxel have been evaluated. Several reports suggested that there is synergistic anti-tumor effect between docetaxel and both 5-FU (30) and S-1 (31, 32).

This phase I study showed that combination therapy with S-1 and weekly docetaxel is active in advanced and recurrent gastric cancer and has an acceptable and manageable toxicity




Figure 4. Kaplan-Meier plot of log-rank analysis for overall survival (OS) and time to progression (TTP). Median overall survival time was 9.4 months. Median time to progression was 2.4 months.

profile. The recommended dose of docetaxel was 20 mg/m<sup>2</sup> administered weekly (treatment on days 1, 8 and 15) in combination with 80 mg/m<sup>2</sup>/day of S-1 for 3 weeks, repeated every 5 weeks. Two investigations (33, 35) previously reported a combination S-1 and once infusional docetaxel. In both studies, the recommended dose of docetaxel was 40 mg/m<sup>2</sup> on day 1 combined with full dose S-1 (80 mg/m<sup>2</sup>) on days 1-14. Although Tomiak *et al.* (36) reported that such a regimen could be repeated every 3 weeks, treatment administration of the next cycle was delayed for a median 7 days because of neutropenia. Yamaguchi *et al.* (33) have described a similar regimen which should be repeated every 4 weeks. Thus, the real dose intensities of S-1 and docetaxel of the previous regimen were 40 mg/m<sup>2</sup>/week and 10 mg/m<sup>2</sup>/week, respectively. In the present study, expected dose intensities of S-1 and docetaxel were 48 mg/m<sup>2</sup>/week and 12 mg/m<sup>2</sup>/week, respectively, and were equivalent or higher than those of the previous regimen. Moreover, the presented weekly docetaxel based regimen is convenient and can be applied on an outpatient basis. In a previous study, docetaxel was found to modulate the level of metabolic enzymes of 5-FU and produced a synergistic effect in a gastric cancer cell line (32), however, in the present study, there were no drug-drug interactions between S-1 and docetaxel.

DLTs with the presented combination were stomatitis and febrile neutropenia. DLTs at the MTD dose level were severe stomatitis. Diarrhea and stomatitis are similar DLT profiles to that found with single use of S-1 and the addition of docetaxel renders this combination more serious. Phase II studies of S-1 monotherapy in patients with advanced gastric cancer showed an overall response rate of 26-49%. In combination S-1 with once infusional docetaxel, response rates were 46-56%. In our study, the overall response rate

was 20%, however, the response rate was 50% at the recommend dose level. The disease control rate of 80% was also promising. With a median survival time of 9.4 months, a median time to progression of 2.4 months, and a median survival time at the recommended dose of 10.0 months, the survival benefit was considered favorable in comparison with median survival times of other regimens, such as docetaxel (6-8 months), S-1 (7-8 months), ECF (10 months) and DCF (10 months).

## Conclusion

The combination of S-1 and weekly docetaxel is an active and well-tolerated regimen in patients with advanced gastric cancer. This regimen can be applied on an outpatient basis, maintaining the dose intensity of both drugs and reducing neutropenia-based side-effects. A phase II trial of the regimen in patients with advanced and recurrent gastric cancer is ongoing.

## Acknowledgements

We thank Erina Hatashita and Yuki Yamada for experimental assistance.

## References

- 1 Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics, 2005. *CA Cancer J Clin* 55: 10-30, 2005.
- 2 Pyrhonen S, Kuitunen T, Nyandoto P and Kouri M: Randomized comparison of fluorouracil, epirubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. *Br J Cancer* 71: 587-591, 1995.



- 3 Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA and Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. *Cancer* 72: 37-41, 1993.
- 4 Glimelius B, Hoffman K, Haglund U, Nyren O and Sjoden PO: Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. *Ann Oncol* 5: 189-190, 1994.
- 5 Macdonald JS, Schein PS, Wooley PV, Smythe T, Ueno W, Hoth D, Smith F, Boiron M, Gisselbrecht C, Brunet R and Lagarde C: 5-fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. *Ann Intern Med* 93: 533-536, 1980.
- 6 Klein HO, Wickramanayake PD, Dieterle F, Mohr R, Oerkermann H and Gross R: High-dose MTX/5-FU and adriamycin for gastric cancer. *Semin Oncol* 10: 29-31, 1983.
- 7 Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, Meyer J, Meyer HJ and Buente H: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. *J Clin Oncol* 7: 1310-1317, 1989.
- 8 Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N and Ford H: A phase II study in advanced gastroesophageal cancer using epirubicin and cisplatin in combination with infusion 5-fluorouracil (ECF). *Ann Oncol* 5: 609-616, 1994.
- 9 Moertel CG, Rubin J, O'Connell MJ, Schutt AJ and Wieand HS: A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. *J Clin Oncol* 4: 1053-1057, 1986.
- 10 Lacave AJ, Baron FJ, Anton LM, Estrada E, De Sande LM, Palacio I, Esteban E, Gracia JM, Buesa JM, Fernandez OA and Gonzalez Baron M: Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. *Ann Oncol* 2: 751-754, 1991.
- 11 Ohtsu A, Yoshida S, Saito D, Shimada Y, Miyamoto K, Fujii T, Yoshino M and Yoshimori M: An early phase II study of 5-fluorouracil combined with cisplatin as a second line chemotherapy against metastatic gastric cancer. *Jpn J Clin Oncol* 21: 120-124, 1991.
- 12 Ohtsu A, Shimada Y, Yoshida S, Saito H, Seki S, Morise K and Kurihara M: Phase II study of protracted infusional 5-fluorouracil combined with cisplatin for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG). *Eur J Cancer* 30A: 2091-2093, 1994.
- 13 Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. *Anticancer Drugs* 7: 548-557, 1996.
- 14 Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of the novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. *Eur J Cancer* 34: 1715-1720, 1998.
- 15 Koizumi W, Kurihara M, Nakano S and Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. *Oncology* 58: 191-197, 2000.
- 16 Chollet P, Schoffski P, Weigang-Kohler K, Schellens JH, Cure H, Pavlidis N, Grunwald V, De Boer R, Wanders J and Fumoleau P, EORTC Early Clinical Studies Group: Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). *Eur J Cancer* 39: 1264-1270, 2003.
- 17 Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M and Urrea P: Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. *J Clin Oncol* 23: 6957-6965, 2005.
- 18 Inokuchi M, Yamashita T, Yamada H, Kojima K, Ichikawa W, Nihei Z, Kawano T and Sugihara K: Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. *Br J Cancer* 94: 1130-1135, 2006.
- 19 Ringel I and Horwitz SB: Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. *J Natl Cancer Inst* 83: 288-291, 1991.
- 20 Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, Wanders J, Franklin H, LeBail N and Verweij J: Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. *Br J Cancer* 70: 380-383, 1994.
- 21 Einzig AI, Neuberg D, Remick SC, Karp DD, O'Dwyer PJ, Stewart JA and Benson III AB: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. *Med Oncol* 13: 87-93, 1996.
- 22 Taguchi T, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J and Hirabayashi N: Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A). *Jpn J Cancer Chemother* 25: 1915-1924, 1998.
- 23 Mai M, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, Hirabayashi N, Taguchi T and Furue A: A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B). *Jpn J Cancer Chemother* 26: 487-496, 1999.
- 24 Bissery MC, Nohynek G, Sanderink GJ and Lavelle F: Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. *Anticancer Drug* 6: 339-368, 1995.
- 25 Park YH, Ryoo B-Y, Choi S-J and Kim H-T: A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. *Br J Cancer* 90: 1329-1333, 2004.
- 26 Chun JH, Kim HK, Lee JS, Choi JY, Hwangbo B, Lee HG, Park SR, Choi IJ, Kim CG, Ryu KW, Kim YW, Lee JS and Bae JM: Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. *Am J Clin Oncol* 28: 188-194, 2005.
- 27 Yoshioka T, Sakata Y, Terashima M, Sekikawa K, Gamoh M, Mitachi Y, Saitoh S and Kanamaru R: Biweekly administration regimen of docetaxel combined with CPT-11 in patients with inoperable or recurrent gastric cancer. *Gastric Cancer* 6: 153-158, 2003.
- 28 Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, Cavalli F, Alberto P, Castiglione M and Goldhirsch A: Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. *Ann Oncol* 11: 301-306, 2000.

- 29 Moiseyenko VM, Ajani JA, Tjiulandin SA, Majlis A, Constenla M, Boni C, Anelli A, Yver AJ and Van Cutsem E, on behalf of the TAX 325 Study Group: Final results of a randomized controlled phase III trial (TAX325) comparing docetaxel (T) combined with cisplatin and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). *Proc Am Soc Clin Oncol* 23: 308s (abstract 4002), 2005.
- 30 Fukushima M, Satake H and Uchida J: Preclinical antitumor efficacy of S1: a new oral formulation of 5-fluorouracil on human tumor xenografts. *Int J Oncol* 13: 693-698, 1998
- 31 Takahashi I, Emi Y, Kakeji Y, Uchida J, Fukushima M and Maehara Y: Increased antitumor activity in combined treatment TS-1 and docetaxel. A preclinical study using gastric cancer xenografts. *Oncology* 68: 130-137, 2005.
- 32 Wada Y, Yoshida K, Suzuki T, Mizuri H, Konishi K, Ukon K, Tanabe K, Sakata Y and Fukushima M: Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. *Int J Cancer* 119: 783-791, 2006.
- 33 Yamaguchi K, Shimamura T, Hyodo I, Koizumi W, Doi T, Narahara H, Komatsu Y, Kato T, Saitoh S, Akiya T, Munakata M, Miyata Y, Maeda Y, Takiuchi H, Nakano S, Esaki T, Kinjo F and Sakata Y: Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. *Br J Cancer* 94: 1803-1808, 2006.
- 34 Yoshida K, Hirabayashi N, Takiyama W, Ninomiya M, Takakura N, Sakamoto J, Nishiyama M and Toge T: Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. *Anticancer Res* 24: 1843-1852, 2004.
- 35 Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J and Nishiyama M: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. *Clin Cancer Res* 12: 3402-3407, 2006.
- 36 Tomiak E, Piccart MJ, Kerger J, Lips S, Awada A, de Valeriola D, Ravoet C, Lossignol D, Sculier JP and Auzannet V: Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. *J Clin Oncol* 12: 1458-1467, 1994.
- 37 Graziano F, Catalano V, Baldelli AM, Giordani P, Testa E, Lai V, Catalano G, Battelli N and Cascinu S: A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. *Ann Oncol* 10: 1263-1266, 2000.
- 38 National Cancer Institute: The revised common toxicity criteria: version 2.0 CTEP website <http://ctep.info.nih.gov>, 1999.
- 39 Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. *J Natl Cancer Inst* 92: 205-216, 2000.

*Received February 26, 2007*

*Revised May 7, 2007*

*Accepted May 8, 2007*

# Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses

Kenji Tamura · Kazuhiko Nakagawa · Takayasu Kurata · Taroh Satoh · Toshiji Nogami · Koji Takeda · Shigeki Mitsuoka · Naruo Yoshimura · Shinzoh Kudoh · Shunichi Negoro · Masahiro Fukuoka

Received: 27 July 2006 / Accepted: 30 October 2006 / Published online: 30 November 2006  
© Springer-Verlag 2006

## Abstract

**Purpose** To determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics of TZT-1027 (soblidotin), a dolastatin 10 analogue, in Japanese patients with advanced solid tumors when administered on days 1 and 8 in 3-week courses.

**Methods** Eligible patients had advanced solid tumors that failed to respond to standard therapy or for which no standard therapy was available, and also met the following criteria: prior chemotherapy  $\leq 2$  regimens, Eastern Cooperative Oncology Group (ECOG) performance status  $\leq 1$ , and acceptable organ function. The MTD was defined as the highest dose at which no more than one of six patients experienced a DLT during course 1. Pharmacokinetic samples were collected in courses 1 and 2.

**Results** Eighteen patients were enrolled in the present study. Three doses (1.5, 1.65, and 1.8 mg/m<sup>2</sup>) were

evaluated. Neutropenia was the principal DLT at doses of 1.65 and 1.8 mg/m<sup>2</sup>. In addition, one patient also experienced grade 3 pneumonia with neutropenia, and another patient experienced grade 3 constipation, neuropathy, grade 4 neutropenia, and hyponatremia as DLTs at 1.65 mg/m<sup>2</sup>. Phlebitis, the most frequent nonhematological toxicity, was improved by administration of additional saline after TZT-1027 administration. The MTD was 1.5 mg/m<sup>2</sup>, at which DLT was not observed in a total of nine patients. The pharmacokinetic profile did not differ from that for the European population. One patient with metastatic esophageal cancer achieved partial response, and each of two patients with non-small cell lung cancer had a minor response.

**Conclusions** When TZT-1027 was administered on days 1 and 8 in 3-week courses to Japanese patients, the MTD was 1.5 mg/m<sup>2</sup> and was lower than the value of 2.4 mg/m<sup>2</sup> in European patients. However, antitumor activity was observed at low doses. TZT-1027 was tolerated well at the MTD, without grade 3 nonhematological toxicities or neutropenia up to grade 2. TZT-1027 is a promising new tubulin polymerization inhibitor that requires further investigation in phase II studies.

K. Tamura · K. Nakagawa · T. Kurata · T. Satoh · T. Nogami · M. Fukuoka

Department of Medical Oncology,  
Kinki University School of Medicine, Osaka, Japan

K. Takeda · S. Negoro

Department of Clinical Oncology,  
Osaka City General Hospital, Osaka, Japan

S. Mitsuoka · N. Yoshimura · S. Kudoh

Department of Respiratory Medicine,  
Osaka City University Medical School, Osaka, Japan

K. Tamura (✉)

Department of Medical Oncology,  
Kinki University School of Medicine,  
Nara Hospital, 1248-1, Otoda, Ikoma,  
Nara 630-0293, Japan  
e-mail: ktamura@nara.med.kindai.ac.jp

**Keywords** Dolastatin · TZT-1027 · Phase I · Antitubulin · Solid tumors

## Introduction

TZT-1027 (*N*<sup>2</sup>-(*N,N*-dimethyl-L-valyl)-*N*-[(1*S*,2*R*)-2-methoxy-4-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]-1-pyrrolidinyl]-1-[(1*S*)-1-methylpropyl]-4-oxobutyl]-*N*-methyl-L-valinamide) is a


synthesized analogue of dolastatin 10, a compound isolated from the marine mollusk *Dolabella auricularia* [9, 17]. The chemical structures of TZT-1027 and dolastatin 10 are shown in Fig. 1.

In *in vitro* studies, TZT-1027 exhibited time-dependent cytotoxicity superior to that of other antitumor agents against a variety of murine and human tumor cell lines [19]. TZT-1027 also exhibited antitumor activity against p-glycoprotein (p-gp)-overexpressing and breast cancer resistant protein (BCRP) positive cell lines established from colon cancer H116 and lung cancer PC-6, and was more potent than vincristine, paclitaxel, and docetaxel. The efficacy of TZT-1027 has been attributed to its inhibitory activity on tubulin polymerization. TZT-1027, believed to interact with tubulin in the same domain as the vinca alkaloid-binding region, inhibits the polymerization of microtubule proteins and the binding of GTP to tubulin [12]. In *in vivo* studies, intravenous injection of TZT-1027 has been shown to potently inhibit the growth of P388 leukemic cells and several solid tumors in mice and to increase life span, with efficacy superior or comparable to that of reference agents, dolastatin 10, cisplatin, vincristine, and 5-fluorouracil [4, 7]. In the xenograft models, furthermore, TZT-1027 reduced intratumoral blood perfusion from 1 to later than 24 h after administration, thus leading to hemorrhagic necrosis of tumor [5, 11, 15]. TZT-1027 exerts antitumor activity through direct cytotoxicity, as well as selective blockade of tumor blood flow, resulting in remarkable antitumor activity. In animal toxicology studies, TZT-1027 had no or little neurotoxic potential in marked contrast to vincristine and paclitaxel which are antimicrotubule agents that have exhibited peripheral neurotoxicity in controlled animal studies [14]. When doses of TZT-1027

were increased, on the other hand, myocardial toxicity was observed in rats and monkeys.

In Japan, a single-dose phase I study was conducted at doses up to 1.35 mg/m<sup>2</sup>, but did not reach the MTD. The major toxicity was neutropenia, and nonhematological toxicities included alopecia, malaise, and anorexia. Therefore, a repeated-dose study of TZT-1027 on days 1, 8, and 15 in 4-week courses followed the single-dose study in Japan. Toxicities were similar, with leucopenia and neutropenia as major toxicities. All episodes of grade 4 neutropenia occurred at doses of 1.5 mg/m<sup>2</sup> or higher. Nonhematological toxicities were mild and did not exceed grade 2 in most patients. Neutropenia was observed as a DLT [13, 20], and the recommended dose was 1.8 mg/m<sup>2</sup>. In Europe, three phase I studies were conducted. A repeated-dose study of TZT-1027 according to the administration schedule on days 1 and 8 in 3-week courses was performed in the Netherlands. This schedule was chosen based on the previous phase I study in Japan, in which TZT-1027 had been administered on days 1, 8, and 15; however, several patients could not receive TZT-1027 on day 15 due to neutropenia; the dose of TZT-1027 was escalated to 2.7 mg/m<sup>2</sup>, with neutropenia and infusion arm pain as DLTs. The recommended dose for phase II studies of TZT-1027 was 2.4 mg/m<sup>2</sup> [2]. Phase II studies are ongoing according to this schedule. Two other administration schedules on day 1 in a 3-week course and on day 1 in a 3- to 4-week course were tested in Germany and Hungary, respectively. In the German study, DLTs—including neutropenia, fatigue, and short-lasting, reversible peripheral neurotoxic syndrome—were observed at 3.0 mg/m<sup>2</sup>. On the other hand, the Hungarian study, enrolling exclusively patients with non-small cell lung cancer, was conducted at doses up to 5.6 mg/m<sup>2</sup> [6, 18]. In these studies, the major toxicities were neutropenia, nausea, vomiting, constipation, alopecia, and injection site pain. The pharmacokinetics of TZT-1027 in these studies appeared linear. The rate of TZT-1027 binding to  $\alpha$ 1-acid glycoprotein, a major plasma protein, was ~95%. In all studies, several patients exhibited a tumor reduction.

Preclinical and clinical data indicated that a suitable administration schedule for the present study would be days 1 and 8 in 3-week courses. The purposes of the present phase I study were to assess the DLTs, to determine the MTD, to observe preliminary antitumor activity, and to study the pharmacokinetics of TZT-1027 that was administered intravenously over 60 min on days 1 and 8 in 3-week courses in Japanese patients with advanced solid tumors. The electrocardiogram (ECG), including QTc interval prolongation, was assessed to estimate cardiovascular side effects.



**Fig. 1** Structural formulae of TZT-1027 and dolastatin 10

## Patients and methods

### Study design

The present study, an open-label, dose-escalating, three-institution phase I study, was conducted in Japanese patients with solid tumors to assess the DLTs, to determine the MTD and preliminary antitumor activity, and to examine pharmacokinetics. A starting dose of 1.8 mg/m<sup>2</sup> was chosen, since this is the recommended dose for the phase II study based on the previous phase I study in Japan, and TZT-1027 was expected to be effective at this dose.

After the MTD was decided, TZT-1027 was administered to three patients at the MTD level to confirm the appropriate recommended dose for phase II studies. TZT-1027 was given intravenously over 60 min with 250 ml of saline on days 1 and 8 in 3-week courses. The present study and the written consent form were approved by the Institutional Review Board. All patients provided informed consent before study entry. The present study was conducted in accordance with the Good Clinical Practice Guidelines as issued by the International Conference on Harmonization and the Declaration of Helsinki.

### Patient eligibility

Patients with histologically or cytologically confirmed solid tumors, which were refractory to standard therapy or for which no effective therapy was available, were eligible to participate in the present study. Other inclusion criteria included the following: no prior chemotherapy or radiotherapy within 4 weeks of study entry (within 6 weeks for nitrosoureas, carboplatin, and mitomycin C; and within 2 weeks for local radiotherapy); not more than two previous regimens of chemotherapy; no previous wide-field radiotherapy to >25% of the bone marrow; age 20–74 years; ECOG performance status, 0 or 1; life expectancy, at least 2 months; adequate bone marrow: hemoglobin  $\geq$  8.5 g/dl, absolute neutrophil count (ANC)  $\geq$  1,500/mm<sup>3</sup>, platelet count  $\geq$  100,000/mm<sup>3</sup>; and normal hepatic functions [serum bilirubin  $\leq$  1.5 mg/dl, and serum aspartate aminotransferase (ALT) and alanine aminotransferase (AST)  $\leq$  2.5 times the upper limit of normal (ULN), respectively]; and renal function (serum creatinine  $\leq$  lower limit of normal). The left ventricular ejection fraction (LVEF), measured by ultrasound cardiography (UCG), had to be  $\geq$  60%. Patients with symptomatic brain metastases or known extensive bone marrow invasion were excluded.

### Treatment and dose escalation

The dose escalation plan consisted of doses of 1.5, 1.65, and 1.8 mg/m<sup>2</sup>. At least three patients were evaluated for the MTD at each dose. If one DLT was observed in a cohort, a total of six patients were enrolled at that dose. The dose escalation was discontinued when two or more of six patients experienced a DLT. The MTD was defined as the highest dose at which no more than one of six patients experienced a DLT during course 1.

The DLT was defined as follows: (a) grade 4 neutropenia with fever ( $>38.0^{\circ}\text{C}$ ) or lasting 5 days or longer; (b) platelet count  $<$  25,000/mm<sup>3</sup>; (c) grade 3/4 nonhematological toxicity excluding nausea and vomiting; (d) grade 3/4 nausea and vomiting with intensive support care; (e) inability to receive TZT-1027 on day 8 in course 1, which was defined as ANC  $<$  1,000/mm<sup>3</sup>, platelet count  $<$  100,000/mm<sup>3</sup>, a DLT by day 8, or the investigator or subinvestigator assessed it to be difficult to initiate administration; and (f) inability to start course 2 up to day 29. Treatment was resumed when meeting all the following criteria: (a) ANC  $\geq$  1,500/mm<sup>3</sup>; (b) platelets  $\geq$  100,000/mm<sup>3</sup>; (c) total bilirubin  $\leq$  1.5 mg/dl; (d) serum creatinine  $\leq$  ULN.

Patients were withdrawn from the present study when they exhibited disease progression or the next course had to be delayed for more than 2 weeks due to any toxicity. The patients were subsequently treated at the dose one level below the level at which the DLT occurred. Toxicity was assessed using the National Cancer Institute Common Toxicity Criteria (version 2.0).

### Treatment assessment

Baseline assessment, including a complete medical history, physical examination, vital signs, ECOG performance status, blood counts, serum biochemistry, and urinalysis, was conducted to assess patient eligibility and had to be completed within 7 days before the start of treatment. Routine biochemistry, hematology, and urinalysis were performed weekly during the treatment course and within 72 h prior to its start. ECG, as well as blood pressure and pulse rate monitoring were performed immediately before and at the end of drip infusion on days 1 and 8 and on day 2 in courses 1 and 2, as well as at the end of the study. The QT interval was corrected for heart rate (QTc) with Bazett's formula ( $\text{QTc} = \text{QT}/\text{RR}^{0.5}$ ). LVEF was performed every two courses. Tumor response was evaluated after every course by RECIST.

## Pharmacokinetic sampling and assay

The pharmacokinetics of TZT-1027 were evaluated on day 1 in courses 1 and 2. Blood samples were collected immediately before drip infusion, at 30 min after the start of the drip infusion, at the end of the drip infusion, and at 30 min and 1, 2, 4, 6, 8, and 23 h after drip infusion. Urine was collected at the following intervals: 0–6 h and 6–24 h after the start of drip infusion. All blood samples were centrifuged immediately after sampling at  $1,200\times g$  for 15 min at  $4^{\circ}\text{C}$ , and the plasma was stored at  $\leq -20^{\circ}\text{C}$  until analysis. Concentrations of TZT-1027 in plasma and urine were determined according to a validated method of high-performance liquid chromatography/mass spectrometry. The lower limit of quantitation was set to 0.25 ng/ml.

## Pharmacokinetic analysis

Pharmacokinetic analysis of the individual plasma and urine concentration data was made using standard model-independent (noncompartmental) methods (WinNonlin Professional 4.0.1; Pharsight Co., Mountain View, CA). The pharmacokinetic parameters included area under the plasma concentration–time curve extrapolated to infinity ( $\text{AUC}_{\text{inf}}$ ) calculated using the linear trapezoidal rule and maximum observed plasma concentration ( $C_{\text{max}}$ ). Total clearance ( $\text{Cl}_{\text{tot}}$ ) was calculated as  $\text{dose}/\text{AUC}_{\text{inf}}$ . Volume of distribution at steady state ( $V_{\text{ss}}$ ) was calculated using clearance and mean residence time. The terminal elimination half-life ( $T_{1/2}$ ) was calculated using concentration data in the terminal log-linear phase. All computations used the actual sampling times. Pharmacokinetic variables are reported as mean  $\pm$  SD. The nadir for ANC was used to assess the relationships between hematological toxicity and pharmacokinetic parameters ( $\text{AUC}_{\text{inf}}$  and  $C_{\text{max}}$ ).

## Results

### General

Eighteen patients, whose characteristics are shown in Table 1, underwent 35 courses of TZT-1027 (median 2; range 1–5) at three doses (Table 2). All 18 patients were assessable for toxicity in course 1. Almost all patients had already received two regimens of chemotherapy. Sixteen patients (89%) had previously received cisplatin or carboplatin therapy, and 12 patients (67%) paclitaxel or docetaxel therapy. Six patients (33%) had previously received radiotherapy.

**Table 1** Patient characteristics

Characteristics	Number of patients
Number of patients (evaluable)	18 (18)
Age, years; median (range)	66 (47–74)
Gender	
Males	16
Females	2
Performance status (ECOG)	
0	2
1	16
Prior treatments	
Chemotherapy	18
Number of regimens	
1	2
2	16
Containing platinum	16
Containing taxane	12
Radiotherapy	6
Tumor types	
Lung	12
Thymoma	2
Rectal	1
Gastric	1
Esophageal	1
Schwannoma	1

Non-small cell lung cancer (NSCLC) was the most common tumor type in the present study.

### Dose-limiting toxicity

TZT-1027 was administered at three different doses (Table 2). At the first dose of  $1.8\text{ mg}/\text{m}^2$ , two of four patients experienced the DLTs including febrile neutropenia and grade 4 neutropenia lasting 11 days. Three patients were then treated at a lower dose of  $1.5\text{ mg}/\text{m}^2$ , without DLT. Five patients were then treated at a dose of  $1.65\text{ mg}/\text{m}^2$ . Three of these five patients experienced the DLTs. One patient suffered grade 3 pneumonia with neutropenia. Another patient had grade 3 constipation, neuropathy, grade 4 neutropenia, and hyponatremia. The other patient developed grade 4 neutropenia and required a delay in starting course 2 due to neutropenia. To confirm the MTD, additional six patients were treated at a dose of  $1.5\text{ mg}/\text{m}^2$ , and no DLTs were observed. Therefore, none of nine patients experienced DLT at  $1.5\text{ mg}/\text{m}^2$ . TZT-1027 was well tolerated without grade 3 nonhematological toxicity or neutropenia up to grade 2 (Table 3), confirming that this dose was indeed the MTD.

At  $1.8\text{ mg}/\text{m}^2$ , one patient developed a DLT on day 14 due to febrile neutropenia and was treated with granulocyte colony stimulating factor (G-CSF) and an antibacterial agent; the patient recovered on day 21 and was subsequently withdrawn from the present study based on the investigator's discretion. Another

**Table 2** Dose escalation scheme and DLTs in course 1

Dose (mg/m <sup>2</sup> )	Number of patients	Number of courses	Number of patients with any DLT/number of patients	ANC: <500/mm <sup>3</sup> for >5 days	Febrile neutropenia	Other grade 3–4 nonhematological toxicities	Inability to receive TZT-1027 on day 8	Inability to start course 2 up to day 29
1.5	9	21	0/9	0	0	0	0	0
1.65	5	9	3/5	0	0	1 <sup>a</sup>	1 <sup>b</sup>	1 <sup>c</sup>
1.8	4	5	2/4	1	1	0	0	0

ANC absolute neutrophil count

<sup>a</sup> Patient with grade 3 pneumonia with neutropenia<sup>b</sup> Patient with grade 3 constipation, neuropathy, grade 4 neutropenia, and hyponatremia<sup>c</sup> Patient with grade 4 neutropenia

patient developed a DLT, i.e., grade 4 neutropenia, at 1.8 mg/m<sup>2</sup> and withdrew in course 1 at his own request due to grade 2 nausea and anorexia. At 1.65 mg/m<sup>2</sup>, two patients developed DLTs, had the next course that was delayed due to neutropenia and pneumonia with neutropenia, required G-CSF and/or antibacterial agents, and recovered within 1 week. The dose for these patients was reduced to 1.5 mg/m<sup>2</sup> after course 1, and one of them subsequently required a further dose reduction to 1.35 mg/m<sup>2</sup> due to grade 4 neutropenia in course 2. Another patient developed DLTs at 1.65 mg/m<sup>2</sup>, with grade 3 constipation, neuropathy, grade 4 neutropenia, and hyponatremia, and recovered with enemas, laxatives, and IV fluids. This patient was subsequently withdrawn from the present study based on the investigator's judgment. No treatment-related deaths were observed.

#### Hematological toxicities

Neutropenia was the major DLT of TZT-1027. Hematological toxicities as functions of the total numbers of patients and courses of TZT-1027 are shown in Table 3. Grade 3 or 4 neutropenia was observed at doses of  $\geq 1.65$  mg/m<sup>2</sup>. No significant neutropenia was observed at 1.5 mg/m<sup>2</sup>, although most patients underwent two or more courses. Both anemia and thrombocytopenia were relatively mild. Thrombocytopenia was only grade 1 in intensity and was observed in all five patients. The median time to ANC nadir was 18 days (range 14–22 days).

#### Nonhematological toxicities

Table 4 shows drug-related nonhematological toxicities observed in any course of treatment. The common nonhematological toxicities were infusion reaction (phlebitis, injection site reaction, and infusion arm pain), anorexia, malaise, nausea, vomiting, and constipation. The most frequently observed toxicity was phlebitis. There were no relationship between all non-hematological toxicities and doses.

In the present study, grade 2 phlebitis was observed in 12 of 18 patients almost always on the next day of administration and nearly completely disappeared in several days thereafter without medication. Four patients experienced grade 1 to 2 pain, three of whom had infusion arm pain. None of these patients experienced "redness" and "swelling" and had venous thrombosis subsequent to phlebitis. On the other hand, phlebitis was rarely observed in European studies [2, 6, 18]. In the present study, phlebitis alleviated when the patient underwent additional flushing consisting of

**Table 3** Hematological toxicities

Dose (mg/m <sup>2</sup> )	Number of patients	Number of courses	Number of patients with dose reduction	Neutropenia				Anemia			Thrombocytopenia	
				All courses (course 1)				All courses (course 1)			All courses (course 1)	
				Grade	1	2	3	4	Grade	1	2	3–4
1.5	9	21	0	2 (1)	4 (4)	0	0	3 (4)	5 (4)	0	2 (2)	0
1.65	5	9	2 <sup>a</sup>	2 (2)	0	0	3 (3)	1 (1)	2 (1)	0	1 (1)	0
1.8	4	5	0	0	0	1 (1)	2 (2) <sup>b</sup>	0	2 (2)	0	1 (1)	0

<sup>a</sup> Dose was reduced in one patient twice

<sup>b</sup> Febrile neutropenia developed in one patient

**Table 4** Nonhematological toxicities

Adverse events	Grade 1	Grade 2	Grade 3	Grade 4
Phlebitis		12		
Anorexia	4	6		
Nausea	3	5		
Alopecia	8			
Malaise	6	1		
Pigmentation disorder	5			
Constipation		3	1	
Vomiting	3	1		
Tenderness	4			
Pain <sup>a</sup>	3	1		
Peripheral neuropathy	1	1	1 <sup>b</sup>	
Injection site reaction	3			
Headache	1	1		
Angiopathy	2			
Diarrhea	2			
Arthralgia	2			
Hematuria	2			
Pyrexia	2			
Pneumonia			1	
Neutropenic infection			1	

Drug-related adverse events (total number of patients: 18)

<sup>a</sup> Three of four patients had infusion arm pain

<sup>b</sup> Neuropathy at baseline was grade 1

200–250 ml of saline over 30–60 min following administration of TZT-1027.

Three patients experienced peripheral neuropathy in course 1 at 1.5 to 1.8 mg/m<sup>2</sup>. Grade 1 neuropathy was observed in one patient at 1.8 mg/m<sup>2</sup>. Another patient developed grade 2 neuropathy at 1.5 mg/m<sup>2</sup>; however, dose reduction was not required during course 2. Another patient at 1.65 mg/m<sup>2</sup> worsened from grade 1 neuropathy at baseline to grade 3 neuropathy with grade 3 constipation on day 5, with recovery on day 13 and day 18, respectively; the patient was not retreated. Apart from the above patient, there were three patients with grade 1 neuropathy at baseline; their disorder did not worsen during the study period.

One patient at 1.65 mg/m<sup>2</sup> experienced pneumonia with grade 3 neutropenia during course 1, was treated with G-CSF and an antibacterial agent, and recovered within 1 week. Therefore, this patient was treated at

1.5 mg/m<sup>2</sup> but again experienced pneumonia without neutropenia during course 2. The patient recovered within 1 week but was not retreated.

Cardiovascular toxicities such as grade 1 hypertension and ventricular arrhythmia were observed. One patient experienced grade 1 hypertension after the first treatment at 1.65 mg/m<sup>2</sup>. The treatment of this patient was interrupted due to the DLTs including grade 3 constipation, neuropathy, grade 4 neutropenia, and hyponatremia. Another patient in the 1.65 mg/m<sup>2</sup> group sporadically experienced grade 1 ventricular arrhythmia at 1.65 mg/m<sup>2</sup> during the study period. All patients underwent 12-lead electrocardiography (ECG) before and after TZT-1027 administration. The 12-lead electrocardiograms had been evaluated by a medical expert on ECG as well as the investigator. Table 5 shows the QTc intervals after each administration of TZT-1027 in courses 1 and 2. The QTc intervals before administration were compared with those after administration, and no significant QTc prolongation was observed.

#### Pharmacokinetics studies

The pharmacokinetics of TZT-1027 were assessed in all patients on day 1 in course 1 (Table 6). Twelve patients receiving TZT-1027 on day 1 in course 2 were also assessed.  $C_{max}$  and  $AUC_{inf}$  tended to increase with dose. However, no statistically significant difference was found among doses. Renal clearance was a minor route of TZT-1027 elimination, since only 1–5% of the dose was excreted unchanged in urine in the first 24 h after administration. Pharmacokinetic parameters were compared between courses 1 and 2. None of  $Cl_{tot}$ ,  $T_{1/2}$ , MRT, and  $V_{ss}$  of TZT-1027 differed between courses 1 and 2 at various doses.

Figure 2 shows that  $Cl_{tot}$  tended to decrease with increases in the plasma concentration of  $\alpha 1$ -AGP ( $r = 0.57$ ). The correlation between  $C_{max}$  or  $AUC_{inf}$  and the nadir for ANC were not clear due to the small dose range. No correlation was found between clearance and body surface area (BSA) ( $r = 0.16$ ).



**Table 5** QT and QTc intervals (mean  $\pm$  SD) at baseline and after administration of TZT-1027 on days 1 and 8 in 3-week courses

	Baseline			Course 2					
	Course 1			Course 2			Course 2		
	D1 after administration <sup>a</sup>	D2	D8 after administration	D1 prior to administration	D1 after administration <sup>a</sup>	D2	D8 prior to administration	D8 after administration <sup>a</sup>	D8 after administration <sup>a</sup>
Number of data (n)	18	17	17	12	12	11	11	11	11
QT (ms)	356 $\pm$ 24	351 $\pm$ 26	356 $\pm$ 25	353 $\pm$ 14	374 $\pm$ 20	357 $\pm$ 14	351 $\pm$ 32	366 $\pm$ 20	366 $\pm$ 20
(min-max)	(320–400)	(300–400)	(314–400)	(330–380)	(350–420)	(330–380)	(310–400)	(330–390)	(330–390)
QTc (ms) <sup>b</sup>	412 $\pm$ 34	424 $\pm$ 21	428 $\pm$ 26	423 $\pm$ 32	413 $\pm$ 25	422 $\pm$ 24	428 $\pm$ 46	429 $\pm$ 20	429 $\pm$ 20
(min-max)	(366–473)	(396–469)	(380–469)	(375–481)	(377–461)	(385–469)	(380–549)	(408–463)	(408–463)

D day

<sup>a</sup> At the end of drip infusion<sup>b</sup> Calculated by Bazett's correction

## Response evaluation

Five of 18 patients were considered not to be evaluable because treatment had ended during course 1 for reasons other than disease progression. One patient with esophageal cancer who had previously received cisplatin plus 5-fluorouracil with radiotherapy had a partial response at 1.65 mg/m<sup>2</sup>. Duration of treatment was 14 weeks. Six of 13 patients exhibited prolonged stable disease. Tumor shrink was observed in two of six patients evaluated as SD. A patient with NSCLC underwent five courses at 1.5 mg/m<sup>2</sup> and showed a 21% tumor reduction and a decrease in pleural effusion. Another patient with NSCLC at 1.65 mg/m<sup>2</sup> showed a 27% tumor reduction. Another patient with gastric cancer in the 1.5 mg/m<sup>2</sup> group who had a metastatic subcutaneous mass was evaluated as exhibiting disease progression due to the detection of a new lesion in a cervical lymph node; however, the mass reduced with necrosis on the next day after treatment, and the mass reduction rate was 29%.


## Discussion

Tubulin is a well-established target for anticancer agents. Although available antitubulin agents, including taxanes and vinca alkaloids, are highly effective in cancer therapy, their clinical usefulness is limited due to intrinsic or acquired resistance and systemic toxicities. Thus, it is important to develop new agents targeting at the tubulin/microtubule system that may be effective against tumors resistant to existing anticancer agents and an improved toxicity profile. A number of potent cytotoxic compounds have been discovered over the past decade, and candidate anticancer agents originating from marine life have been examined in human clinical trials. Of these compounds, dolastatin 10 and dolastatin 15 have been extensively evaluated in clinical studies. An analogue of dolastatin 15, cemadotin, underwent several administration schedules of phase I studies and showed a major DLT of neutropenia, apart from cardiac toxicity and hypertension [10]. A dolastatin 15 analogue tasidotin exhibited dose-limiting toxicities including neutropenia, ileus, and elevated transaminase levels [1, 3]. Phase I studies of dolastatin 10 were performed, and its DLT was neutropenia [8, 16].

TZT-1027 is designed with the goal of maintaining potent antitumor activity and reducing the toxicities of the parent compound. In mice, intravenous injection of TZT-1027 showed equivalent or greater efficacy than dolastatin 10. On the basis of the preclinical data, a

**Table 6** Pharmacokinetic parameters of TZT-1027 on day 1 in course 1

Dose (mg/m <sup>2</sup> )	Number of patients	C <sub>max</sub> , ng/ml (mean, cv%)	AUC <sub>inf</sub> , ng h/ml (mean, cv%)	Cl <sub>tot</sub> , l/h/m <sup>2</sup> (mean, cv%)	V <sub>ss</sub> , l/m <sup>2</sup> (mean, (cv%)	T <sub>1/2</sub> , h (mean, cv%)
1.5	9	186.0 (31.1)	427.8 (37.9)	4.2 (48.3)	16.7 (46.1)	5.7 (11.7)
1.65	5	211.3 (29.3)	573.2 (45.4)	3.4 (46.3)	19.2 (20.3)	7.6 (32.8)
1.8	4	200.3 (20.9)	502.8 (10.7)	3.6 (10.4)	22.6 (37.3)	7.4 (30.5)

**Fig. 2** Correlation between  $\alpha$ 1-AGP and the clearance of TZT-1027

repeated-dose study of TZT-1027 on days 1, 8, and 15 was conducted in Japan. The DLT according to the administration schedule was neutropenia. The MTD was determined to be less than 2.1 mg/m<sup>2</sup>, and the recommended dose for phase II studies was considered to be 1.8 mg/m<sup>2</sup> [13, 20]. In that study, however, 14 of 40 patients could not receive TZT-1027 on day 15 on schedule due to toxicities. Therefore, a repeated-dose study on days 1 and 8 in 3-week courses was conducted in patients with solid tumors in the Netherlands, in whom TZT-1027 was escalated to 2.7 mg/m<sup>2</sup>. Consequently, the DLTs were neutropenia and infusion arm pain. The recommended dose for phase II studies of TZT-1027 was determined to be 2.4 mg/m<sup>2</sup>.

In the previous phase I study in the Netherlands, the recommended dose for phase II studies was 2.4 mg/m<sup>2</sup>. Grade 3 neutropenia was observed in only 2 of >39 courses at 2.4 mg/m<sup>2</sup>. To standardize the criterion on performance status with that in the Netherlands study and to exclude the influence of the prior chemotherapy to an extent possible, selection criteria were limited in the present study. The median value for the regimen of pretreatment was two courses in the both present and Netherlands study. Major differences between the present study and the previous study in the Netherlands were predominant types of tumor (NSCLC versus several tumors) and median age (66 versus 53 years old, respectively). The pharmacokinetic profiles of TZT-1027

were similar between the present study and the study in the Netherlands. In the Netherlands study at 1.8 mg/m<sup>2</sup>, AUC<sub>inf</sub>, C<sub>max</sub>, T<sub>1/2</sub>, and Cl<sub>tot</sub> were 728.1 ng h/ml, 240.4 ng/ml, 6.65 h, and 4.7 L/h, respectively. It seems difficult to explain based on PK parameters alone why the MTD in the present study differed from that in the Netherlands. On the other hand, three of four patients in the repeated-dose study on days 1, 8, and 15 in Japan did not receive TZT-1027 on day 8 on schedule due to neutropenia at 2.1 mg/m<sup>2</sup>, and one of four patients at 1.8 mg/m<sup>2</sup> in that study underwent no treatment on day 8 due to neutropenia. Between Japanese and European patients receiving TZT-1027, therefore, a difference appeared to exist especially in the severity of bone marrow toxicity.

In the present study, phlebitis was frequently observed as compared with European studies. No significant difference was found in the administration schedule between the present study and the study in the Netherlands. Other frequent nonhematological toxicities were anorexia, nausea, alopecia, constipation, and malaise similarly to European studies. In contrast to other dolastatin analogues, such as a dolastatin 15 analogue tasidotin, increased ALT or AST was rare.

In a previous study according to an administration schedule on day 1 in 3-week courses in Germany, neurotoxicity as a DLT was observed with two of five patients who were treated above the MTD (2.7 mg/m<sup>2</sup>). Both patients had previously received oxaliplatin [18], leading us to conjecture that oxaliplatin predisposes neurotoxicity. In the present study, no patients had been treated previously with oxaliplatin. The neurotoxic influence of TZT-1027 after oxaliplatin should be considered in preclinical studies.

In contrast to the above dolastatin analogues, little cardiovascular toxicity was observed in the present study. Initial studies of cemadotin, a dolastatin 15 analogue, revealed severe hypertension. In the present study, therefore, we measured blood pressure and pulse rate, and conducted the 12-lead ECG before and after TZT-1027 administration for QT interval determination. There was no significant prolongation of the QTc interval at any time point.

Dose intensity in the present study was lower than that in the European studies. However, a partial

response was observed in a patient with metastatic esophageal cancer previously treated by radiochemotherapy. Antitumor activity in previously treated metastatic NSCLC was also seen in two patients who experienced a 21% tumor reduction, including a decrease in pleural effusion during five courses, and a 27% tumor reduction. Metastatic subcutaneous tumor in gastric cancer patient reduced with necrosis on the next day after TZZ-1027 administration, with a tumor reduction rate of 29%. Preclinical studies have demonstrated the potent in vitro cytotoxicity of TZZ-1027 against several tumor cell lines and its in vivo antivascular effects, e.g., disruption of the tumor vasculature.

In conclusion, the present study showed that TZZ-1027, a synthetic analogue of the natural marine product dolastatin 10, is effective for Japanese patients with advanced solid tumors when administered on days 1 and 8 in 3-week courses, possesses an improved safety profile as compared with other dolastatin analogues, and is active at a tolerable dose.

## References

- Cunningham C, Appleman LJ, Kirvan-Visovatti M, Ryan DP, Regan E, Vukelja S, Bonate PL, Ruvuna F, Fram RJ, Jekunen A, Weitman S, Hammond LA, Eder JP Jr (2005) Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors. *Clin Cancer Res* 11:7825–7833
- de Jonge MJ, van der Gaast A, Planting AS, van Doorn L, Lems A, Boot I, Wanders J, Satomi M, Verweij J (2005) Phase I and pharmacokinetic study of the dolastatin 10 analogue TZZ-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. *Clin Cancer Res* 11:3806–3813
- Ebbinghaus S, Rubin E, Hersh E, Cranmer LD, Bonate PL, Fram RJ, Jekunen A, Weitman S, Hammond LA (2005) A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors. *Clin Cancer Res* 11:7807–7816
- Fujita F, Koike M, Fujita M, Sakamoto Y, Tsukagoshi S (2000) Antitumor effects of TZZ-1027, a novel dolastatin 10 derivative, on human tumor xenografts in nude mice. *Jpn J Cancer Chemother* 27:451–458
- Hashiguchi N, Kubota T, Koh J, Yamada Y, Saikawa Y, Otani Y, Watanabe M, Kumai K, Kitajima M, Watanabe J, Kobayashi M (2004) TZZ-1027 elucidates antitumor activity through direct cytotoxicity and selective blockage of blood supply. *Anticancer Res* 24:2201–2208
- Horti J, Juhasz E, Bodrogi I, Ikeda S (2003) A phase I trial of TZZ-1027, an inhibitor of tubulin polymerization, in patients with advanced non-small cell lung cancer (NSCLC). *AACR-NCI-EORTC Abstr* 256
- Kobayashi M, Natsume T, Tamaoki S, Watanabe J, Asano H, Mikami T, Miyasaka K, Miyazaki K, Gondo M, Sakakibara K, Tsukagoshi S (1997) Antitumor activity of TZZ-1027, a novel dolastatin 10 derivative. *Jpn J Cancer Res* 88:316–327
- Madden T, Tran HT, Beck D, Huie R, Newman RA, Pusztai L, Wright JJ, Abbruzzese JL (2000) Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. *Clin Cancer Res* 6:1293–1301
- Miyazaki K, Kobayashi M, Natsume, Gondo M, Mikami T, Sakakibara K, Tsukagoshi S (1995) Synthesis and antitumor activity of novel dolastatin 10 analogs. *Chem Pharm Bull* 43:1706–1718
- Mross K, Herbst K, Berdel WE, Korfel A, von Broen IM, Bankmann Y, Hossfeld DK (1996) Phase I clinical and pharmacokinetic study of LU103793 (Cemadotin hydrochloride) as an intravenous bolus injection in patients with metastatic solid tumors. *Onkologie* 19:490–495
- Natsume T, Watanabe J, Koh Y, Fujio N, Ohe Y, Horiuti T, Saijo N, Nishio K, Kobayashi M (2003) Antitumor activity of TZZ-1027 (soblidotin) against endothelial growth factor-secreting human lung cancer in vivo. *Cancer Sci* 94:826–833
- Natsume T, Watanabe J, Tamaoki S, Fujio N, Miyasaka K, Kobayashi M (2000) Characterization of the interaction of TZZ-1027, a potent antitumor agent, with tubulin. *Jpn J Cancer Res* 91:737–747
- Niitani H, Hasegawa K, Furuse K, Fukuoka M, Horikoshi N, Kudoh S (1998) Phase I studies of TZZ-1027, a novel inhibitor of tubulin polymerization. *Ann Oncol* 9 (Suppl 2) Abstr 360
- Ogawa T, Mimura Y, Isowa K, Kato H, Mitsuishi M, Toyoshi T, Kuwayama N, Morimoto H, Murakoshi M, Nakayama T (2001) An antimicrotubule agent, TZZ-1027, does not induce neuropathologic alterations which are detected after administration of vincristine or paclitaxel in animal models. *Toxicol Lett* 121:97–106
- Otani M, Natsume T, Watanabe, Kobayashi M, Murakoshi M, Mikami T, Nakayama T (2000) TZZ-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. *Jpn J Cancer Res* 91:837–844
- Pilot HC, McElroy EA, Reid JM, Windebank AJ, Sloan JA, Erlichman C, Bagniewski PG, Walker DL, Rubin J, Goldberg RM, Adjei AA, Ames MM (1999) Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. *Clin Cancer Res* 5:525–531
- Pettit GR, Kamano Y, Herald CL, Tuiman AA, Boettner FE, Kizu H, Schmidt JM, Baczynskyj L, Tomer KB, Bontems Rj (1987) The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. *J Am Chem Soc* 109:6883–6885
- Schoffski P, Thate B, Beutel G, Bolte O, Otto D, Hofman M, Ganser A, Jenner A, Cheverton P, Wanders J, Oguma T, Atsumi R, Satomi M (2004) Phase I and pharmacokinetic study of TZZ-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. *Ann Oncol* 15:671–679
- Watanabe J, Natsume T, Fujio N, Miyasaka K, Kobayashi M (2000) Induction of apoptosis in human cancer cells by TZZ-1027, an antimicrotubule agent. *Apoptosis* 5:345–353
- Yamamoto N, Andoh M, Kawahara M, Fukuoka M, Niitani H (2002) Phase I study of TZZ-1027, an inhibitor of tubulin polymerization, given weekly x 3 as a 1-hour intravenous infusion in patients (pts) with solid tumors. *Proc Am Soc Clin Oncol* 21:Abstr 420

# Amrubicin for non-small-cell lung cancer and small-cell lung cancer

Takayasu Kurata · Isamu Okamoto · Kenji Tamura · Masahiro Fukuoka

Received: 28 May 2007 / Accepted: 12 June 2007 / Published online: 13 July 2007  
© Springer Science + Business Media, LLC 2007

**Summary** Amrubicin is a totally synthetic anthracycline anticancer drug and a potent topoisomerase II inhibitor. Recently, amrubicin was approved in Japan for the treatment of small- and non-small-cell lung cancers (SCLC and NSCLC). Here, we review the efficacy and toxicities of amrubicin monotherapy and amrubicin in combination with cisplatin for extensive-disease SCLC (ED-SCLC), and of amrubicin monotherapy for advanced NSCLC, as observed in the clinical trials. Recommended dosage for previously untreated advanced NSCLC was 45 mg/m<sup>2</sup>/day by intravenous administration for 3 days. Dose-limiting toxicities were leucopenia, thrombocytopenia, and gastrointestinal disturbance. Response rate was 27.9% for advanced NSCLC, and 75.8% for ED-SCLC with a median survival time (MST) of 11.7 months. Recommended dosage of amrubicin was 40 mg/m<sup>2</sup>/day in combination with cisplatin at 60 mg/m<sup>2</sup>/day, with MST of 13.6 months and 1-year survival rate of 56.1%. In sensitive or refractory relapsed SCLC, response rate was 52 and 50%, progression-free survival was 4.2 and 2.6 months, overall survival was 11.6 and 10.3 months, and 1-year survival rate was 46 and 40%, respectively. These results are promising for the treatment of both NSCLC and SCLC. Further clinical trials will clarify the status of amrubicin in the treatment of lung cancer.

**Keywords** Amrubicin · Anthracycline · Topoisomerase II inhibitor · Non-small-cell lung cancer · Small-cell lung cancer

## Introduction

Amrubicin is a totally synthetic anthracycline anticancer drug based on doxorubicin, of which the hydroxyl group at position 9 has been replaced by an amino group in amrubicin to enhance the efficacy. This new derivative is believed to exhibit its antitumor effect through metabolic reduction in tumor cells and conversion to the active metabolite amrubicinol, which inhibits cell growth about 200 times as potently as the parent compound (Fig. 1), [1, 2] unlike other anthracycline anticancer drugs, such as doxorubicin, in which the metabolites are considered to have a weaker antitumor effect than the parent compound. In comparison with doxorubicin *in vivo*, amrubicin was shown to have a more potent antitumor effect and lower toxic effects on the heart, a site of delayed toxicity with doxorubicin, and on the liver and kidneys [3, 4]. *In vivo* comparison between single dose and repeated doses of amrubicin over five consecutive days in antitumor effects on several cell lines revealed superior antitumor effect for 5-day administration, demonstrating schedule dependence (Table 1) [5]. With respect to the mechanism of action, amrubicin seems to act on topoisomerase II, stabilizing a cleavable complex [6]. As for clinical trials, a single-dose phase I study was first performed in patients with various types of previously treated malignant tumors. Adverse events that were defined as dose-limiting toxicities (DLTs) were hematologic, including leucopenia, thrombocytopenia, and anemia; the maximum tolerated dose (MTD) was 130 mg/m<sup>2</sup>, and the recommended dose for phase II clinical studies was set at 100 mg/m<sup>2</sup> [7]. Next, a phase I clinical study using five-consecutive-day administration was performed in patients with various types of previously treated malignant tumors. As expected, the DLT was myelosuppression, while the MTD was 25 mg/m<sup>2</sup> with a total dose of

T. Kurata (✉) · I. Okamoto · K. Tamura · M. Fukuoka  
Department of Medical Oncology,  
Kinki University School of Medicine,  
377-2 Ohno-Higashi, Osaka-Sayama,  
Osaka 589-8511, Japan  
e-mail: ctc002@poh.osaka-med.ac.jp